ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Combination Regenerative Therapy

Its studies are mostly in Hearing Loss, Noise-Induced, led by Truway Health.

Furthest: early phase 1, since Mar 8, 20261 company-led study, 1 open or runningNext primary completion: Mar 8, 2097 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Truway Health11 open or runningearly phase 1since Mar 8, 2026Mar 8, 2026Mar 8, 2097early phase 1 · NCT07472023

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2026First study: early phase 1 study in Hearing Loss, SensorineuralFirst studyNCT07472023 · 120 planned · United States

Ahead

  1. Mar 8, 2097Primary completion: early phase 1 study in Hearing Loss, SensorineuralNCT07472023

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07472023Hearing Loss, Sensorineural · United StatesEarly 1By invitationMar 8, 2097120

How it is read

Names in the registry

  • “Combination Regenerative Therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.